ReviewImmunology and allergy clinics of North America2015
Novel Therapies for Eosinophilic Disorders.
Review in Immunology and allergy clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Analysis of Cardiovascular Risk Factors in Patients with Psoriasis: A Cross-Sectional Study.Mediterranean journal of rheumatology · 2025Article
- Differential Neutrophil and Eosinophil Infiltrations in the Sub-Lining Compartment of Rheumatoid Versus Osteoarthritic Synovium.Mediterranean journal of rheumatology · 2025Article
- The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.Advances in respiratory medicine · 2025Article
- Article
- Current and emerging biologic therapies targeting eosinophilic disorders.The World Allergy Organization journal · 2022Review
- Emerging Evidence for Pleiotropism of Eosinophils.International journal of molecular sciences · 2021Review
- Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?Frontiers in immunology · 2021Review
- Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report.Cancer immunology, immunotherapy : CII · 2021Article
- Contributions of Eosinophils to Human Health and Disease.Annual review of pathology · 2020Review
- The eosinophil: For better or worse, in sickness and in health.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018Review
- Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).Journal of leukocyte biology · 2018Review
- Eosinophils in Autoimmune Diseases.Frontiers in immunology · 2017Review
- Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins.Frontiers in medicine · 2017Review
- Recent advances in understanding eosinophil biology.F1000Research · 2017Review
- "Siglec"ting the allergic response for therapeutic targeting.Glycobiology · 2016Review
- Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.Current opinion in allergy and clinical immunology · 2016Review
- Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.Current opinion in allergy and clinical immunology · 2016Review
- Eosinophilic bioactivities in severe asthma.The World Allergy Organization journal · 2016Review
- Eosinophils: The unsung heroes in cancer?OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.